RxDoctor Payments Data

Krishna Goli, MD

Neurology · Fayetteville, GANPI 1932384427

Payments from drug & device makers

$8,247in general payments, 2019–2025

Across 465 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$735
  • Biogen$572
  • Novartis$523
  • Teva Pharmaceuticals USA, Inc.$419
  • Amgen$310
  • plus $4K from 54 others

What the payments were for

  • Consulting fees$1502%
  • Speaking & faculty fees$240%
  • Food & beverage$7,89496%
  • Education$1792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)87$1,195
UCB, Inc.43$735
Biogen24$572
Novartis47$523
Teva Pharmaceuticals USA, Inc.17$419
Amgen(2 entities)16$310
AstraZeneca(2 entities)18$309
Greenwich Biosciences, Inc.9$263
MDD US Operations, LLC8$220
Sanofi11$217
Pfizer10$194
Lilly USA, LLC11$182
Sunovion Pharmaceuticals Inc.12$158
Acadia Pharmaceuticals Inc8$151
Amneal Pharmaceuticals LLC9$149
Lundbeck LLC7$147
Neurelis, Inc.6$138
Avanir Pharmaceuticals, Inc.9$129
Genentech USA, Inc.7$123
Takeda Pharmaceuticals U.S.A., Inc.5$107
TG Therapeutics, Inc.4$104
GE HealthCare7$103
ANI Pharmaceuticals, Inc.5$101
GRT US Holding, Inc.2$101
CSL Behring4$99
W. L. Gore & Associates, Inc.3$93
SK Life Science, Inc.4$86
EMD Serono, Inc.5$81
Neurocrine Biosciences, Inc.4$81
Otsuka America Pharmaceutical, Inc.4$78
Upsher-smith Laboratories LLC4$77
Supernus Pharmaceuticals, Inc.5$77
Argenx US, Inc.4$69
Acorda Therapeutics, Inc3$63
Harmony Biosciences LLC2$60
Eisai Inc.4$59
Grifols USA, LLC3$55
Adamas Pharmaceuticals, Inc.3$50
Aprecia Pharmaceuticals, LLC2$43
Bausch Health US, LLC2$43
Microtransponder, Inc.2$37
Zyla Life Sciences, Inc.3$37
Endo Pharmaceuticals Inc.2$36
Assertio Therapeutics, Inc.2$35
Vertical Pharmaceuticals, LLC2$34
Aucta Pharmaceuticals, Inc.2$34
Banner Life Sciences, LLC1$27
Vanda Pharmaceuticals Inc.1$26
Scilex Pharmaceuticals Inc.1$23
Abbott1$23
Mallinckrodt Hospital Products Inc.1$22
Biohaven Pharmaceutical Holding Company Ltd.1$20
Merz Pharmaceuticals, LLC1$19
Akcea Therapeutics, Inc.1$19
Avion Pharmaceuticals1$18
Jazz Pharmaceuticals Inc.1$18
Johnson & Johnson1$18
Mallinckrodt Enterprises LLC1$17
Kyowa Kirin, Inc.1$16
Sumitomo Pharma America, Inc.1$4

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,247 in reported general payments places this provider in the 70th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$71,919
Medicare patients
403
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab14$730,576
Aimovig AutoinjectorErenumab-Aooe141$132,500
QuliptaAtogepant54$75,100
NeuproRotigotine47$55,399
GlatopaGlatiramer Acetate23$51,708
NuedextaDextromethorphan Hbr/Quinidine26$44,931
Emgality PenGalcanezumab-Gnlm43$39,282
BriviactBrivaracetam19$29,664
UbrelvyUbrogepant19$25,562
NourianzIstradefylline13$24,462
Emgality SyringeGalcanezumab-Gnlm20$19,658
Memantine Hcl690$18,522
Dimethyl Fumarate42$16,260
Dalfampridine ErDalfampridine24$15,131
Rivastigmine89$13,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris, Brilinta$309$735,94725 claims
AbbVieQulipta, Ubrelvy, Namzaric$1,195$107,84285 claims
UCB, Inc.Neupro, Briviact$735$85,06366 claims
Avanir Pharmaceuticals, Inc.Nuedexta$129$44,93126 claims
Kyowa Kirin, Inc.Nourianz$16$24,46213 claims
PfizerDilantin$194$6,31414 claims
Johnson & JohnsonXarelto$18$5,17911 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$149$2,98238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 506 neurology providers in Georgia.

Other neurology in Fayetteville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →